Winner of Innovation Challenge to Receive $25,000 Grant

NEW YORK, NY, USA February 8, 2021 – Last month, Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, launched its first Innovation Challenge for 2021 in the area of Thriving with Transplantation. The Challenge goal is to identify new ways to help organ transplant recipients better manage their numerous daily challenges and experiences.

The global Innovation Challenge, sponsored by CSL Behring, will take place virtually in May 2021 and is open to patient entrepreneurs – those who have been affected by chronic disease as either a patient,  support partner for a loved one or know someone who motivated them to start a company to develop solutions to an unmet need identified in their disease journey.

“As someone living with two organ transplants and managing the rigorous demands of being a CEO of a health-based start-up, I know first hand the many challenges that organ transplant recipients face each and every day,” explains Dr. Karin Hehenberger, CEO and Founder of Lyfebulb and transplant recipient. “At the heart of our Innovation Challenge, Lyfebulb and CSL Behring are eager to identify tangible and meaningful solutions to alleviate patient worries and improve their quality of life. Our goal is to invite fresh thinking and brilliant ideas to help organ transplant recipients not only survive but even thrive with their conditions by addressing the many obstacles, small and large, that they encounter daily.”

Submissions may span devices, diagnostics, consumer products, products for healthcare professionals, and healthcare IT to manage transplants, as well as support overall physical and mental well-being. Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. To apply or learn more, please visit:

The Innovation Challenge is one component of a larger partnership between Lyfebulb and CSL Behring to generate new solutions to better serve members within the transplant community. Please visit https://www.transplantlyfe.com to see the digital engagement platform, launched by Lyfebulb in partnership with CSL, for the transplant community. 

About Lyfebulb

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, substance use disorder, migraine, transplantation, psoriasis, chronic cough, and chronic kidney disease. See Lyfebulb.comFacebookTwitterInstagramKarin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring

For more information:

Lyfebulb Contact:

Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210
Email: karin@lyfebulb.com

January 31, 2018 will always be a special day for me, as that was the day that, through the selfless act of donation, I received my second chance at life with a heart transplant. Before that day, I was told that without a new heart, I would have a year or so left to live. Now, I can do things I never dreamed I could prior to transplant; I love to hike and exercise, love to volunteer with our local Organ Procurement Agency, and my family and I started a nonprofit last year, Heartfelt Help Foundation that assists Bay Area heart transplant recipients with both sourcing and paying for the right kind of medically required post-transplant housing. Though this temporary relocation is required, it is, at best, only minimally covered by insurance and that is where we come in. All of this is possible, because of an organ donor.

NEW YORK, Feb. 3, 2021 — Patient empowerment platform, Lyfebulb, and TRIO (Transplant Recipients International Organization) announced today their partnership to provide the transplant community with the support they need during their journey. Lyfebulb recently launched TransplantLyfe, which enables community members to make connections to each other, share stories, participate in Q&A forums, access information through vetted resources and create journals to track biometrics and other health measurements over time.

Through this partnership, TRIO members will be able to directly link to the TransplantLyfe site from the TRIO website and engage with an international group of transplant patients, care partners, donors and other interested parties. Similarly, TransplantLyfe members will have access to TRIO’s expert resources on the TransplantLyfe platform. Together, Lyfebulb and TRIO will create new content for the community in the form of webinars and other online events, engaging both the TRIO and Lyfebulb communities.

“TRIO is proud to partner with Lyfebulb in supporting the growth of TransplantLyfe,” said Jim Gleason, President, TRIO National. “We hear time and again from our community that people are searching to find someone who has gone through this journey before. But there are only around 39,000 transplants done in the US in one year – it is hard to find these patients.”

TransplantLyfe allows users to share their questions and experiences with a group and to find a 1:1 connection without being limited to their local community. The goal is to enable patients, care partners and donors to reduce the uncertainty in their journey and inspire them to thrive with their transplant experience, not just survive.

TransplantLyfe was developed with the support of CSL Behring, a global biotechnology leader.

“It is very encouraging to have the support and partnership of so many strong stakeholders in the transplant community,” said Karin HehenbergerMD, PhD, Founder & CEO, Lyfebulb. “As a two time transplant recipient, I have always seen this need for an organized and curated community platform and it is gratifying to see others recognize and support it as well.”

For more information on TransplantLyfe or to register, please visit https://www.transplantlyfe.com/.

About Lyfebulb

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, substance use disorder, migraine, transplantation, psoriasis, chronic cough, and chronic kidney disease.

See Lyfebulb.comFacebookTwitterInstagramKarin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About TRIO

TRIO is an independent , not-for-profit international organization committed to improving the quality of life of transplant candidates, recipients, their families and the families of organ and tissue donors. Through the TRIO headquarters and a network of chapters, TRIO serves its members in the areas of awareness, support, education and advocacy.

See www.trioweb.org.

Lyfebulb Contact:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210
Email: karin@lyfebulb.com

TRIO Contact:
Jim Gleason, TRIO National President
Phone: + 1 609-877-4493 [OR Mobile: (610) 999-0341]
E-mail: GleasonJim@aol.com

Alisha is a fiery, poetic redhead living on the Canadian prairies. After complications due to a metabolic liver condition she was diagnosed with shortly after birth, she received a liver transplant in August 2020. She is a grief embodiment worker, speaker and writer raising awareness for organ donation and medical trauma. She lives with her husband and their rescue puppy and is a lover of coffee and all things cozy.

Winning Entry to Receive $25,000 Grant

NEW YORK, NY, USA January 7, 2021 – Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, unveils the launch of their 2021 Innovation Challenge: Thriving with Transplantation. The goal of this initiative is to source innovative solutions to improve outcomes and experiences for all those affected by organ transplantation.

The Innovation Challenge, sponsored by CSL Behring, will take place virtually in May 2021 and is open to patient entrepreneurs – those who have been affected by chronic disease as either a patient or support partner for a loved one and started a company to develop solutions to an unmet need identified in their disease journey.

“We are thrilled to kick-off the new year with the announcement of an initiative that sparked Lyfebulb’s founding in 2014.” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb and transplant recipient. “Having personally experienced the complications of living with chronic disease, Lyfebulb was founded upon the core principles that patients need patients and patients can be innovators. We are honored to be working with our partner, CSL Behring, to amplify that messaging and further inspire innovation to help people not just survive, but thrive.”

Submissions may span devices, diagnostics, consumer products, products for healthcare professionals, and healthcare IT to directly treat or manage transplants, as well as support overall physical and mental well-being. Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. To apply or learn more, please visit:

“Innovation is a core value at CSL Behring,” said Kevin Kovaleski, Vice President, Global Commercial Development, Transplant, CSL Behring. “Supporting ventures like this Innovation Challenge is fundamental to understanding the challenges that transplant recipients are really experiencing in day-to-day life, and ultimately, improving outcomes for patients.”

The Innovation Challenge is one component of a larger partnership between Lyfebulb and CSL Behring to generate new solutions to better serve members within the transplant community.

About Lyfebulb

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, substance use disorder, migraine, transplantation, psoriasis, chronic cough, and chronic kidney disease. See Lyfebulb.comFacebookTwitterInstagramKarin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring

For more information:

Lyfebulb Contact:

Karin Hehenberger, MD, PhD

CEO & Founder, Lyfebulb

Phone: + 1 917-575-0210

Email: karin@lyfebulb.com

CHALLENGE TIMELINE

January 7, 2021
Applications Open
February 19, 2021
Submission Deadline
March 16, 2021
Finalist Announcement
May 12-13, 2021
Innovation Challenge
May 13, 2021
Winner Announcement

ABOUT THE SUMMIT AND AWARD

The goal of the 2021 Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation is to source innovative solutions to improve outcomes and experiences for all those affected by transplantation.

The Innovation Challenge will take place virtually in May 2021 and is currently accepting applications through February 19, 2021. Patient entrepreneurs – those who have been affected by chronic disease as either a patient or support partner for a loved one and started a company to develop solutions to an unmet need identified in their disease journey – are encouraged to apply.

Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. Beyond presenting their innovative ventures, the finalists will have the opportunity to exchange ideas on how to further advance patient innovation in the transplant community; engage with Lyfebulb founders, CSL Behring leadership leadership, representatives from the patient community, key opinion leaders and potential investors; and share insights with each other.

The Lyfebulb-CSL Behring Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on the issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).

SHARE

JUDGING CRITERIA

The judging panel will assess the following:

UNMET NEED

  • What is the strategic basis for the identified problem/gap (e.g., research conducted)?
  • How is the problem/gap being specifically addressed?

IMPACT

  • Does the innovation have the potential to improve the lives of people affected by transplantation?
  • How great of an impact (market impact and patient impact) will the innovation make and how will it be measured?

MARKET FEASIBILITY

  • How is the product or service unique to the market?
  • What is the feasibility of development and implementation into the marketplace (e.g., funding, regulations, requirements for testing)?

APPLYING FOR THE INNOVATION CHALLENGE

Submissions should focus on innovative solutions with the potential to improve outcomes and experiences using devices, diagnostics, consumer products, products for healthcare professionals, digital healthcare or healthcare IT to directly treat or manage transplants, or support overall physical and mental well-being.

The solution may address the following:

INNOVATION

  • Directly treating or managing transplant
  • Supporting overall physical and mental well-being

KEY STAKEHOLDERS

  • Patients (recipients), donors, families, and loved ones
  • Medical community and society

STAGE OF JOURNEY

  • All stages of the journey from pre-transplantation through long-term management

THE CHALLENGE IN NUMBERS

7

JANUARY

Applications open on Wednesday, January 7, 2021

19

February

Applications close on Friday, February 19, 2021, at 11:59 PM EDT

2

Days

Finalists will be pitch their solutions over the course of a two day summit May 12-13, 2021

$25

Thousand

One entrepreneur will be awarded the 2021 Lyfebulb-CSL Behring Innovation Award, including a $25,000 monetary grant to grow their company

Born and raised along the shoreline of California, Caleigh has spent the last decade living in San Francisco. Diagnosed at birth with cystic fibrosis, Caleigh maintained her health through sports and social activities. Despite her best efforts to balance health, career, and happiness, she found herself battling diabetes and end-stage lung disease, frequently hospitalized, sustaining nutrition through a feeding tube, breathing with the help of supplemental oxygen and bi-pap and in need of a double lung transplant. In order to financially and mentally survive the isolating nature of her situation she began chronically her journey and beginning her own legacy through her blog and now foundation, Fight2Breathe. A year after her first transplant, Caleigh experienced severe rejection and was in desperate need for a second life-saving double lung transplant. She moved to Los Angeles and spent 6 months living in the hospital while waiting for her surgery. Since receiving her new lungs, she lives an independent and successful life achieving new goals every day – including being a wish granter for the Make A Wish Foundation and public speaking for other organizations such as the Cystic Fibrosis Foundation, Global Genes, One Legacy, Donate Life, and Sick Chicks. She celebrates others through helping those who are in similar situations any way possible.